Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Exela Technologies, Inc is a software—application business based in the US. Exela Technologies shares (XELA) are listed on the NASDAQ and all prices are listed in US Dollars. Exela Technologies employs 21,000 staff and has a trailing 12-month revenue of around USD$1.4 billion.
Since the stock market crash in March caused by coronavirus, Exela Technologies's share price has had significant positive movement.
Its last market close was USD$0.3589, which is 17.28% up on its pre-crash value of USD$0.2969 and 317.33% up on the lowest point reached during the March crash when the shares fell as low as USD$0.086.
If you had bought USD$1,000 worth of Exela Technologies shares at the start of February 2020, those shares would have been worth USD$437.16 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$980.60.
|Latest market close||USD$0.3589|
|52-week range||USD$0.086 - USD$0.8409|
|50-day moving average||USD$0.3943|
|200-day moving average||USD$0.4024|
|Wall St. target price||USD$1.55|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.197|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-15)||N/A|
|1 month (2020-10-26)||-12.06%|
|3 months (2020-08-22)||N/A|
|6 months (2020-05-22)||N/A|
|1 year (2019-11-22)||N/A|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
Valuing Exela Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exela Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Exela Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$87.5 million.
The EBITDA is a measure of a Exela Technologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.4 billion|
|Gross profit TTM||USD$337.6 million|
|Return on assets TTM||-0.04%|
|Return on equity TTM||0%|
|Market capitalisation||USD$61.6 million|
TTM: trailing 12 months
There are currently 4.8 million Exela Technologies shares held short by investors – that's known as Exela Technologies's "short interest". This figure is 15.1% down from 5.7 million last month.
There are a few different ways that this level of interest in shorting Exela Technologies shares can be evaluated.
Exela Technologies's "short interest ratio" (SIR) is the quantity of Exela Technologies shares currently shorted divided by the average quantity of Exela Technologies shares traded daily (recently around 6.2 million). Exela Technologies's SIR currently stands at 0.78. In other words for every 100,000 Exela Technologies shares traded daily on the market, roughly 780 shares are currently held short.
However Exela Technologies's short interest can also be evaluated against the total number of Exela Technologies shares, or, against the total number of tradable Exela Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exela Technologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Exela Technologies shares in existence, roughly 30 shares are currently held short) or 0.1615% of the tradable shares (for every 100,000 tradable Exela Technologies shares, roughly 162 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Exela Technologies.
Find out more about how you can short Exela Technologies stock.
We're not expecting Exela Technologies to pay a dividend over the next 12 months.
Over the last 12 months, Exela Technologies's shares have ranged in value from as little as $0.086 up to $0.8409. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exela Technologies's is 2.2178. This would suggest that Exela Technologies's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Exela Technologies, Inc. provides transaction processing solutions, enterprise information management, document management, and digital business process services worldwide. The company operates through three segments: Information & Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal & Loss Prevention Services (LLPS). The ITPS segment provides lending solutions for mortgages and auto loans; banking solutions for clearing, anti-money laundering, sanctions, and interbank cross-border settlement; property and casualty insurance solutions for origination, enrollments, claims processing, and benefits administration communications; and public sector solutions for income tax processing, benefits administration, and records management. It also offers solutions for payment processing and reconciliation, integrated receivable and payables management, document logistics and location services, records management, and electronic storage of data/documents; and software, hardware, professional services, and maintenance related to information and transaction processing automation. The HS segment provides revenue cycle solutions, integrated accounts payable and accounts receivable, and information management for healthcare payer and provider markets. The LLPS segment processes legal claims for class action and mass action settlement administrations, involving project management support, notification, and outreach to claimants; and collects, analyzes, and distributes settlement funds. It also offers data and analytical services in the area of litigation consulting, economic and statistical analysis, expert witness services, and revenue recovery services for delinquent accounts receivable. The company is headquartered in Irving, Texas.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.